Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 4/20 | 0.62 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2354288 | 0.96 | PLA2G4B (0.60) | RARBPLA2G4BTP53TSHRKDM4E | |
| SCHEMBL12733015 | 0.87 | L3MBTL1 (0.58) | PLA2G4BKDM4ECYP1A2CYP2D6PDE4A | |
| SCHEMBL6201125 | 0.87 | HRH2 (0.61) | PLA2G4BTP53TSHRKDM4ECYP1A2 | |
| SCHEMBL13767448 | 0.84 | RARB (0.59) | RARBPLA2G4BTP53TSHRKDM4E | |
| SCHEMBL31441005 | 0.83 | RARB (0.54) | RARBPLA2G4BKDM4ECYP1A2CYP2D6 | |
| SCHEMBL9000228 | 0.83 | PLA2G4B (0.79) | RARBPLA2G4BTP53TSHRKDM4E | |
| SCHEMBL10347634 | 0.83 | RARB (0.54) | RARBTP53TSHRALDH1A1 | |
| SCHEMBL9361466 | 0.82 | PPARA (0.49) | PLA2G4B | |
| SCHEMBL28567793 | 0.81 | L3MBTL1 (0.62) | KDM4ESMN1; SMN2LMNA | |
| Bicarbonate SCHEMBL7805312 | 0.81 | RARB (0.74) | RARBPLA2G4BTP53TSHRHDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010020104-A1 | Process for preparing substituted benzyl compounds and toluene derivatives | CLARIANT GMBH | 2001-09-06 | — | — | US | disclosed |
| EP-1127861-A1 | Method to synthesise substituted benzyl and toluene compounds | Clariant GmbH (DE) | 2001-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020104-A1 | Process for preparing substituted benzyl compounds and toluene derivatives | NISCH, TBCB, NBAS | RARB 1694/4885PLA2G4B 4555/4885TP53 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.